- Home
- BEAM
as of 02-18-2026 3:39pm EST
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
| Founded: | 2017 | Country: | US |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.7B | IPO Year: | 2019 |
| Target Price: | $46.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.32 | EPS Growth: | -166.28 |
| 52 Week Low/High: | $13.53 - $36.44 | Next Earning Date: | 04-01-2026 |
| Revenue: | $24,000 | Revenue Growth: | 33.33% |
| Revenue Growth (this year): | -38.24% | Revenue Growth (next year): | 22.06% |
| P/E Ratio: | -8.30 | Index: | N/A |
| Free Cash Flow: | -356192000.0 | FCF Growth: | N/A |
AI-Powered BEAM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
CEO
Avg Cost/Share
$28.64
Shares
25,000
Total Value
$708,946.50
Owned After
986,667
CEO
Avg Cost/Share
$29.47
Shares
25,000
Total Value
$734,581.95
Owned After
986,667
Chief Legal Officer
Avg Cost/Share
$34.00
Shares
1,371
Total Value
$46,614.00
Owned After
95,667
SEC Form 4
SVP, Finance and Treasurer
Avg Cost/Share
$35.00
Shares
6,198
Total Value
$216,933.10
Owned After
34,813
SEC Form 4
SVP, Finance and Treasurer
Avg Cost/Share
$30.12
Shares
3,034
Total Value
$91,384.08
Owned After
34,813
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$34.58
Shares
18,629
Total Value
$644,831.51
Owned After
95,667
Chief Legal Officer
Avg Cost/Share
$27.10
Shares
1,254
Total Value
$33,983.40
Owned After
95,667
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$27.10
Shares
6,294
Total Value
$170,567.40
Owned After
73,706
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Evans John M. | BEAM | CEO | Jan 30, 2026 | Sell | $28.64 | 25,000 | $708,946.50 | 986,667 | |
| Evans John M. | BEAM | CEO | Jan 29, 2026 | Sell | $29.47 | 25,000 | $734,581.95 | 986,667 | |
| Bellon Christine | BEAM | Chief Legal Officer | Jan 22, 2026 | Sell | $34.00 | 1,371 | $46,614.00 | 95,667 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Jan 22, 2026 | Sell | $35.00 | 6,198 | $216,933.10 | 34,813 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Jan 20, 2026 | Sell | $30.12 | 3,034 | $91,384.08 | 34,813 | |
| Bellon Christine | BEAM | Chief Legal Officer | Jan 15, 2026 | Sell | $34.58 | 18,629 | $644,831.51 | 95,667 | |
| Bellon Christine | BEAM | Chief Legal Officer | Dec 31, 2025 | Sell | $27.10 | 1,254 | $33,983.40 | 95,667 | |
| Emany Sravan Kumar | BEAM | Chief Financial Officer | Dec 31, 2025 | Sell | $27.10 | 6,294 | $170,567.40 | 73,706 |
Compare BEAM vs Leading Stocks
See how BEAM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.